- Home
- PHAR vs CHY Comparison
PHAR vs CHY Comparison
Compare PHAR & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- CHY
- Stock Information
- Founded
- PHAR 1988
- CHY 2003
- Country
- PHAR Netherlands
- CHY United States
- Employees
- PHAR N/A
- CHY N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- PHAR Health Care
- CHY Finance
- Exchange
- PHAR Nasdaq
- CHY Nasdaq
- Market Cap
- PHAR 731.1M
- CHY 839.8M
- IPO Year
- PHAR N/A
- CHY N/A
- Fundamental
- Price
- PHAR $10.00
- CHY $11.00
- Analyst Decision
- PHAR Strong Buy
- CHY
- Analyst Count
- PHAR 3
- CHY 0
- Target Price
- PHAR $30.00
- CHY N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- CHY 128.3K
- Earning Date
- PHAR 07-31-2025
- CHY 01-01-0001
- Dividend Yield
- PHAR N/A
- CHY 10.11%
- EPS Growth
- PHAR N/A
- CHY N/A
- EPS
- PHAR N/A
- CHY N/A
- Revenue
- PHAR $320,708,000.00
- CHY N/A
- Revenue This Year
- PHAR $13.31
- CHY N/A
- Revenue Next Year
- PHAR $7.68
- CHY N/A
- P/E Ratio
- PHAR N/A
- CHY N/A
- Revenue Growth
- PHAR 24.13
- CHY N/A
- 52 Week Low
- PHAR $6.65
- CHY $9.97
- 52 Week High
- PHAR $12.61
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- CHY 66.03
- Support Level
- PHAR $9.99
- CHY $10.96
- Resistance Level
- PHAR $10.59
- CHY $11.11
- Average True Range (ATR)
- PHAR 0.35
- CHY 0.09
- MACD
- PHAR -0.14
- CHY 0.01
- Stochastic Oscillator
- PHAR 7.45
- CHY 81.36
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.